openPR Logo
Press release

Extracorporal Modified Immune Therapy (EMIT)

03-17-2016 01:31 PM CET | Health & Medicine

Press release from: PBirkel

A tumor patient usually does not die from a benign tumor, but from a malignant tumor that maintains an uninhibited proliferation, which in turn interferes fatally with the vital functions of other organs.

Apart from surgical procedures at an early stage, conventional cancer therapy is based on the philosophy that cancer cells should be destroyed with various destructive methods such as chemotherapy, radiation therapy, TKI, monoclonal antibodies, etc. All immunological research approaches also aim to destroy tumor cells; metaphorically speaking either by increasing the number of police officers (NK, T-cells etc.) or by re-arming them with more powerful weapons. Even the latest efforts with PD-1, CTLA-4 or CAR-T for cancer treatments are nothing else but a kind of “chemotherapy” with biological instrumentation. Apart from some few cancer entities which may indeed thus be treated successfully, this approach has only a limited effect and is applied merely with life-prolonging or palliative intention, not to mention of their unpredictable and high toxicity (more informationen).

EMIT follows an alternative way of action: On the basis of immunological instruction, malignant tumor cells are transformed into benign tumor cells. In the course of aging processes, the tumor cells recede and die off gradually (see images). After treatment, a residual tumor may still persist, but it is merely a harmless lump of abnormal tissue. In contrast to conventional therapies, the immune cells generated by EMIT remain almost a lifetime in the body, and they henceforth survey over the growth of tumor cells in question till the end of life.

What is necessary for performing an EMIT therapy? All we need is a piece tumor of 1-2 cm³ size containing living tumor cells, as well as some blood sample of patient approximately every third week. Depending on growth and reaction, cultured cells must then be re-injected into the patient about once per week. The whole treatment requires approximately 3 months.

Dr. med Sadik Öz (SOEZMED):
- STUDY (1979 − 1985)
Human Medicine at the University of Regensburg ( Physikum ) or University Erlangen-Nuremberg
- MEDICAL EDUCATION (1988 − 1995)
in the Med . Klinik III Uni – Erlangen Med . Clinic IV , Klinikum Nürnberg and Med . Clinic V , Nuremberg Hospital
- CANCER RESEARCH (SINCE 1981)
September 1981 – September 1985 − Doctoral thesis
September 1985 – August 1986 − Assistant Professor at the Department of Immunology and Rheumatology,
Med . Klinik III Uni – Erlangen
September 1986 – June 1987 − Researcher at the Sloan Kettering Cancer Center, New York, USA
July 1987 – January 1988 − MHH Hannover Pediatric Oncology
February 1988 – December 1991 − Med. Klinik III Uni-Erlangen Haematological malignancies
July 1991 – August 1995 − Med. Klinik V, Klinikum Nürnberg Haematological malignancies
September 1995 to date − Independent researcher
- DOCTOR’S SURGERY SINCE 1995

Dr. med. Sadık Öz, Feuerweg 21, 90443 Nürnberg, +49 911 92919620
contact@soezmed.com

Pressecontact:
Peter Birkel
Bogenstr. 5
91233 Neunkirchen
Tel. + 49 9123 14957
Mail: birkel2334@googlemail.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Extracorporal Modified Immune Therapy (EMIT) here

News-ID: 326710 • Views: 438

More Releases from PBirkel

03-17-2016 | Health & Medicine
PBirkel
The new concept: EMIT - CANCER IS CURABLE
The new concept: EMIT - CANCER IS CURABLE In the course of approximately 30 years in cancer research (see curriculum vitae) I have been trying to work out a new strategy to overcome the problems mentioned above. Based on my observations I assume that the mode of therapy should comprise not only the destruction of the tumor cell, but should focus on its “conversion”, “re-education” into normal functioning body cells. I
03-15-2016 | Health & Medicine
PBirkel
An alternative cancer treatment: Extracorporal Modified Immune Therapy (EMIT)
EMIT is based on the special cultivation of somatic tumor cells and leucocytes of patients, it would be subject to such regulation, too. Due to such financial and administrative obstacles it is almost impossible to offer this promising treatment for public use.  If a physician acts against these regulations, this would be regarded as an indictable offence as mentioned above. Moreover, other problems emerge: Those who do not belong to academic
03-14-2016 | Health & Medicine
PBirkel
May renal cell carcinoma be cured by EMIT?
A 50 year-old male patient asked for help: A left-sided renal mass had been detected in an abdominal CT-scan performed due to a preceding gross hematuria. Abdominal CT-scan: Inhomogeneous tumor with a diameter of approximately 9.5 cm in the left kidney. Additionally, several enlarged aortic lymph nodes (about 8 mm in size) as well as a tumor in the left adrenal with a diameter of 10 mm. Pathological evaluation Macroscopy: Left kidney,

All 4 Releases


More Releases for Med

CAS MED SPA OFFERS COOLSCULPTING PROMOTION
MARIETTA, GEORGIA- APRIL 29, 2019- CAS MED SPA is excited to announce its CoolSculpting service, as well as a money saving promotional code. Available on their website at https://cs.cassmedspa.com/cas-coolsculpting-best-offer, patients can save $200 off their treatment. Going on through SPRING 2019, CAS MED SPA offers their best deal ever, up to $1500 with the purchase of six or more treatments! CoolSculpting is a revolutionary way to eliminate body fat. Unlike liposuction
Global Cochlear Implants Market 2018 - Cochlear, MED-EL, Sonova, Microson
Apex Market Reports, recently published a detailed market research study focused on the “Cochlear Implants Market” across the global, regional and country level. The report provides 360° analysis of “Cochlear Implants Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Cochlear Implants on
Global Neurostimulator Devices Market 2018 - Schiller, Abiomed, MED-EL, Avazzia
The statistical surveying information incorporated into the Neurostimulator Devices report is the aftereffect of significant essential and optional research exercises. The report fragments the global Neurostimulator Devices market based on makers, item compose, applications, and regions. In this report, each fragment is contemplated completely and measurements are introduced in detail. The report offers an exact outline of the global Neurostimulator Devices advertise covering key factors, for example, drivers and restrictions
EuropeSpa med quality standards published in book form
Internationally valid quality and safety criteria for health and medical wellness listed in a comprehensive compendium Stuttgart/Wiesbaden, 3 September 2012 | The European Spas Association has published the EuropeSpa med criteria for medical spas and medical wellness providers. The book Quality Standard for Medical Spas and Medical Wellness Providers in Europe was unveiled today by publishing house Schweizerbart Verlag (www.schweizerbart.de) in Stuttgart. For the first time, this compendium sets out about
Nano Med Tech Researchers Develop Application to Improve Antibiotics
Nano Med Tech researchers are developing multi-chambered nanoparticles that are attracted to infected cells but harmless to healthy tissues. When integrated into antibiotics, they will make the drugs much more effective by ensuring that they reach only those cells in need of treatment. As the particles have been specifically engineered to penetrate through the bacterial cell membranes, researchers are confident that these new drugs should be far more effective
Nano Med Tech Hires Stateside Sales Team
Nano Med Tech, a newly emerging leader in nano-technological cancer research and treatment, announced that its sales team for America is in place and that stateside medical marketing will commence, soon. With a Commercial Director and eight account managers in place, Nano Med Tech will now seek to make its technology available in medical institutions throughout the United States. The organization has received USFDA approval for several patented medical devices, which utilize advanced